BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15932357)

  • 21. Guillain-Barré syndrome in northwest Greece.
    Markoula S; Giannopoulos S; Sarmas I; Tzavidi S; Kyritsis AP; Lagos G
    Acta Neurol Scand; 2007 Mar; 115(3):167-73. PubMed ID: 17295711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guillain-Barré syndrome in the elderly: clinical, electrophysiological, therapeutic and outcome features.
    França MC; Deus-Silva L; de Castro R; Garibaldi SG; Pfeilsticker BH; Nucci A; Marques JF
    Arq Neuropsiquiatr; 2005 Sep; 63(3B):772-5. PubMed ID: 16258654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome.
    Chi LJ; Wang HB; Zhang Y; Wang WZ
    J Neuroimmunol; 2007 Dec; 192(1-2):206-14. PubMed ID: 17997492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanical ventilation in Guillain-Barré syndrome: does age influence functional outcome?
    Köhrmann M; Huttner HB; Nowe T; Schellinger PD; Schwab S
    Eur Neurol; 2009; 61(6):358-63. PubMed ID: 19365128
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical variants of Guillain-Barre syndrome: some aspects of differential diagnosis.
    Dididze MN
    Georgian Med News; 2009 Jan; (166):48-51. PubMed ID: 19202218
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long term disability and social status change after Guillain-Barré syndrome.
    Bersano A; Carpo M; Allaria S; Franciotta D; Citterio A; Nobile-Orazio E
    J Neurol; 2006 Feb; 253(2):214-8. PubMed ID: 16096809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with health-related quality of life in patients with severe Guillain-Barré syndrome.
    Demir SO; Köseoğlu F
    Disabil Rehabil; 2008; 30(8):593-9. PubMed ID: 17852306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conservative treatment of lumbar disc disease: patient's quality of life compared to an unexposed cohort.
    Schneider C; Krayenbühl N; Landolt H
    Acta Neurochir (Wien); 2007 Aug; 149(8):783-91; discussion 791. PubMed ID: 17624490
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Campylobacter jejuni and cytomegalovirus (CMV) infections in patients with the Guillain-Barre syndrome].
    Orlikowski D; Quijano-Roy S; Sivadon-Tardy V; Raphael JC; Gaillard JL
    Arch Pediatr; 2006 Dec; 13(12):1561-5. PubMed ID: 17030119
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Residual disability 10 years after falling ill in Guillain-Barré syndrome: a prospective follow-up study.
    Forsberg A; Press R; Holmqvist LW
    J Neurol Sci; 2012 Jun; 317(1-2):74-9. PubMed ID: 22425539
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuromuscular respiratory failure in Guillain-Barre Syndrome: evaluation of clinical and electrodiagnostic predictors.
    Sundar U; Abraham E; Gharat A; Yeolekar ME; Trivedi T; Dwivedi N
    J Assoc Physicians India; 2005 Sep; 53():764-8. PubMed ID: 16334619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Guillain-Barré syndrome treated by membrane plasma exchange and/or immunoadsorption.
    Marn Pernat A; Buturović-Ponikvar J; Svigelj V; Ponikvar R
    Ther Apher Dial; 2009 Aug; 13(4):310-3. PubMed ID: 19695065
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinically diagnosed Guillain-Barre syndrome in Ile-Ife, Nigeria.
    Sunmonu TA; Komolafe MA; Adewuya A; Olugbodi AA
    West Afr J Med; 2008 Jul; 27(3):167-70. PubMed ID: 19256323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term sensory deficit after Guillain-Barré syndrome.
    Bernsen RA; Jager AE; Schmitz PI; van der Meché FG
    J Neurol; 2001 Jun; 248(6):483-6. PubMed ID: 11499638
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [High-dose intravenous immunoglobulins for treatment of optic neuritis in Guillain-Barré syndrome].
    Lüke C; Dohmen C; Dietlein TS; Brunner R; Lüke M; Krieglstein GK
    Klin Monbl Augenheilkd; 2007 Dec; 224(12):932-4. PubMed ID: 18260057
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complete recovery of an aged patient with Guillain-Barré syndrome associated with multiple IgM anti-ganglioside antibodies.
    Furiya Y; Hirano M; Kusunoki S; Ueda M; Sugie K; Nishiwaki T; Ueno S
    Muscle Nerve; 2008 Dec; 38(6):1630-3. PubMed ID: 19016534
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GQ1b antibody testing in Guillain-Barre syndrome and variants.
    Chaudhry F; Gee KE; Vaphiades MS; Biller J; Jay W
    Semin Ophthalmol; 2006; 21(4):223-7. PubMed ID: 17182410
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical presentation and course of childhood Guillain-Barré syndrome: a prospective multicentre study.
    Korinthenberg R; Schessl J; Kirschner J
    Neuropediatrics; 2007 Feb; 38(1):10-7. PubMed ID: 17607598
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional outcome at 2.5, 5, 9, and 24 months after injury in the Netherlands.
    Polinder S; van Beeck EF; Essink-Bot ML; Toet H; Looman CW; Mulder S; Meerding WJ
    J Trauma; 2007 Jan; 62(1):133-41. PubMed ID: 17215744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Acute polyradiculoneuropathy. Guillain-Barre syndrome].
    Turki I; Djaïet S; Boukhris S; Hentati F
    Tunis Med; 2003 Oct; 81(10):781-7. PubMed ID: 17722794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.